Search research articles
Contact Us
Filters
Showing results (21-30 of 133) with videos related to
Page
of 14
Sort By:
Leukemia
|
January 18, 2019
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver, Richard F Schlenk, Nigel H Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2024
Reply to S. Fuji
Mark J Levis, Mehdi Hamadani, Mary M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2019
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Mark J Levis, Yi-Bin Chen, Mehdi Hamadani, et al.
Cancer Medicine
|
December 19, 2020
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Jessica K Altman, Alexander E Perl, Jason E Hill, et al.
Blood Advances
|
February 7, 2022
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Catherine C Smith, Mark J Levis, Alexander E Perl, et al.
American Journal of Hematology
|
February 24, 2021
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia
Amir T Fathi, Eytan M Stein, Courtney D DiNardo, et al.
Oncotarget
|
March 28, 2020
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
Tomoya Aikawa, Noriko Togashi, Koichi Iwanaga, et al.
Blood Cancer Discovery
|
September 30, 2021
A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors
David J Young, Bao Nguyen, Li Li, et al.
Blood Advances
|
March 23, 2019
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, et al.
The American Journal of Medicine
|
April 13, 2016
Carotidynia Heralding the Onset of Acute Leukemia
Laura A Sena, Alexander J Ambinder, Alison R Moliterno, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 133) with videos related to
Sort By:
Page
of 14
Leukemia
|
January 18, 2019
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver, Richard F Schlenk, Nigel H Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2024
Reply to S. Fuji
Mark J Levis, Mehdi Hamadani, Mary M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2019
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Mark J Levis, Yi-Bin Chen, Mehdi Hamadani, et al.
Cancer Medicine
|
December 19, 2020
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Jessica K Altman, Alexander E Perl, Jason E Hill, et al.
Blood Advances
|
February 7, 2022
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Catherine C Smith, Mark J Levis, Alexander E Perl, et al.
American Journal of Hematology
|
February 24, 2021
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia
Amir T Fathi, Eytan M Stein, Courtney D DiNardo, et al.
Oncotarget
|
March 28, 2020
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
Tomoya Aikawa, Noriko Togashi, Koichi Iwanaga, et al.
Blood Cancer Discovery
|
September 30, 2021
A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors
David J Young, Bao Nguyen, Li Li, et al.
Blood Advances
|
March 23, 2019
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, et al.
The American Journal of Medicine
|
April 13, 2016
Carotidynia Heralding the Onset of Acute Leukemia
Laura A Sena, Alexander J Ambinder, Alison R Moliterno, et al.
Page
of 14